ストックスクリーナーアプリを入手
72.10
0.28%
0.20
前日終値:
$71.90
開ける：
$71.9
24時間の取引高:
6.78M
Relative Volume:
1.36
時価総額：
$27.82B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
30.84
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
+16.99%
1か月 パフォーマンス:
+13.70%
6か月 パフォーマンス:
+19.71%
1年 パフォーマンス:
-15.01%
1日の値動き範囲:
$71.31
$73.05
1週間の範囲:
$61.54
$73.05
52週間の値動き範囲:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.10 | 27.74B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Dexcom stock (US2521311074): earnings beat and fresh institutional interest keep CGM story in focus - AD HOC NEWS
DexCom Inc. stock outperforms competitors on strong trading day - MSN
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Does DexCom’s (DXCM) Flex Launch in Germany Hint at a Broader CGM Access Strategy Shift? - simplywall.st
Elliott strikes Dexcom board settlement after taking stake - MSN
6-Day Rally Sends DexCom Stock Up 25% - Trefis
Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It (NYSEARCA:DEXC) - Seeking Alpha
DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside - Yahoo Finance
Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery - Insider Monkey
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Stock Rockets 24% With 5-Day Winning Streak - Trefis
Dexcom stock (US2521311074): diabetes-tech player draws attention after Q1 earnings beat - AD HOC NEWS
DexCom Might Finally Be Cheap Enough (NASDAQ:DXCM) - Seeking Alpha
Here's why DexCom (DXCM) is a strong momentum stock - MSN
[144] DEXCOM INC SEC Filing - Stock Titan
Dexcom stock (US2521311074): Insider sale adds focus on shares - AD HOC NEWS
The DexCom Stock Turnaround Is Showing Real Signs of Life - Yahoo Finance
Here's Why DexCom (DXCM) is a Strong Momentum Stock - Yahoo Finance
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
Dexcom stock (US2521311074): Insider sale and sharp price jump put CGM specialist in focus - AD HOC NEWS
Dexcom (NASDAQ: DXCM) legal chief sells 1,700 shares under 10b5-1 plan - Stock Titan
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany - Zacks Investment Research
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Devon Energy Corp stock (US2521311074): earnings momentum and oil price tailwinds in focus - AD HOC NEWS
A Look at DexCom Inc (DXCM) After 5.6% Gain -- GF Value $102.05 vs Price $65.09 - GuruFocus
Dexcom Inc. stock (US2521311074): buyback, 2030 targets and activist deal fire up DXCM - AD HOC NEWS
DexCom : Operations and Innovation Committee - marketscreener.com
DexCom, Inc.Common Stock (NQ: DXCM - The Chronicle-Journal
DexCom Is Maintained at Buy by Canaccord Genuity - Moomoo
A Potential Turnaround Stock In Digital Healthcare - Good Money Guide
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients - GuruFocus
DexCom Price Target Cut to $80.00/Share From $100.00 by B of A Securities - Moomoo
Dexcom stock (US2521311074): Analyst moves follow Elliott deal and new long-term targets - AD HOC NEWS
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany - 01net
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces - GuruFocus
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading - StocksToTrade
Dexcom Reveals Flex CGM for Type 2 Diabetes Patients - Medical Product Outsourcing
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside - TradingView
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
DexCom Expands CGM Access in Germany With New Dexcom Flex System for Type 2 Diabetes - Moomoo
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $82 - Moomoo
BofA Securities Adjusts Price Target on DexCom to $80 From $100 - marketscreener.com
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management - TIKR.com
DexCom, Inc. (DXCM) Stock Analysis: 33.77% Potential Upside Attracts Investor Attention - DirectorsTalk Interviews
Dexcom Inc. stock (US2521311074): diabetes tech player in focus after recent share move - AD HOC NEWS
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
DexCom, Inc. (DXCM) Analyst/Investor DaySlideshow (NASDAQ:DXCM) 2026-05-17 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Stephens Investment Management Group LLC Boosts Stock Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
0.22%
大文字化:
|
ボリューム (24 時間):